Statin therapy and the development of cerebral amyloid angiopathy: a rodent in vivo approach
Background: Cerebral amyloid angiopathy (CAA) is characterized by vascular deposition of amyloid β (Aβ) with a higher incidence of cerebral microbleeds (cMBs) and spontaneous hemorrhage. Since statins are known for their benefit in vascular disease we tested for the effect on CAA. Methods: APP23-tra...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
19 January 2016
|
| In: |
International journal of molecular sciences
Year: 2016, Volume: 17, Issue: 1 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms17010126 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.3390/ijms17010126 Verlag, Volltext: https://www.mdpi.com/1422-0067/17/1/126 
|
| Author Notes: | Björn Reuter, Alexander Venus, Saskia Grudzenski, Patrick Heiler, Lothar Schad, Matthias Staufenbiel, Michael G. Hennerici and Marc Fatar |
| Summary: | Background: Cerebral amyloid angiopathy (CAA) is characterized by vascular deposition of amyloid β (Aβ) with a higher incidence of cerebral microbleeds (cMBs) and spontaneous hemorrhage. Since statins are known for their benefit in vascular disease we tested for the effect on CAA. Methods: APP23-transgenic mice received atorvastatin-supplemented food starting at the age of eight months (n = 13), 12 months (n = 7), and 16 months (n = 6), respectively. Controls (n = 16) received standard food only. At 24 months of age cMBs were determined with T2*-weighted 9.4T magnetic resonance imaging and graded by size. Results: Control mice displayed an average of 35 ± 18.5 cMBs (mean ± standard deviation), compared to 29.3 ± 9.8 in mice with eight months (p = 0.49), 24.9 ± 21.3 with 12 months (p = 0.26), and 27.8 ± 15.4 with 16 months of atorvastatin treatment (p = 0.27). In combined analysis treated mice showed lower absolute numbers (27.4 ± 15.6, p = 0.16) compared to controls and also after adjustment for cMB size (p = 0.13). Conclusion: Despite to a non-significant trend towards fewer cMBs our results failed to provide evidence for beneficial effects of long-term atorvastatin treatment in the APP23-transgenic mouse model of CAA. A higher risk for bleeding complications was not observed. |
|---|---|
| Item Description: | Gesehen am 17.01.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms17010126 |